Abstrakt

Hepatitis C virus (HCV) infection is a worldwide problem and hepatitis, which is its natural unfavourable course, is still a challenge for hepatologist. At present, standards of treatment are changing from combined therapy with interferon alpha (IFN-α) and ribavirin to new antiviral drugs. The current classification divides interferon induced thyroid diseases (IITD) into two groups: autoimmune (Hashimoto disease, Graves disease, positive antithyroid autoantibodies in euthyroid patients) and non-autoimmune (destructive thyroiditis, non-autoimmune hypothyroidism). A common complication of cytokine therapy is the induction of antithyroid autoantibodies de novo without thyroid dysfunction. During therapeutic regimens combined with ribavirin, destructive thyroiditis with typical biphasic course is more common than in IFN-α monotherapy. Clinically, overt pathologies often have discrete symptoms, which cause diagnostic and therapeutic dilemmas. Aims: The aim of this study was to estimate IITD occurrence, to find risk factors for IITD development. Material and methods: The study group consisted of 66 patients treated for HCV infection. Before and during antiviral therapy, hormonal (TSH, fT4, fT3), immunological (thyroid autoantibodies), ultrasonographic and genetic (HLA-A2) parameters were evaluated. Results: Hormonal disturbances were detected in 24.2% of patients; however, 43.9% of patients had positive thyroid autoantibodies (de novo) without hormonal imbalance. Multivariate analysis revealed the following: female sex, elevated TSH level, occurrence of anti-TPO autoantibodies (TPO-Ab), and increased blood velocity in thyroid arteries are risk factors for IITD development. Thyroid disorders are common during IFN-α therapy. Previous epidemiological data seem to be underestimated. Important risk factors for IITD development are: female sex, elevated serum TSH concentration (≥2.5 μU/mL), positive TPO-Ab and increased blood velocity in thyroid arteries.

Przypisy

• 1. A Special Meeting Review Edition: Advances in the treatment of hepatitis C virus infection from EASL 2013: The 48th Annual Meeting of the European Association for the Study of the Liver April 24-28. Gastroenterol. Hepatol. (N Y), 2013; 9 (Suppl. 3): 1-18
  Google Scholar
• 2. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Ghinoi A., Rotondi M., Ferrannini E.: Thyroid disorders in chronic hepatitis C virus infection. Thyroid, 2006; 16: 563-572
  Google Scholar
• 3. Benaiges D., Garcia-Retortillo M., Mas A., Canete N., Broquetas T., Puigvehi M., Chillarón J.J., Flores-Le Roux J.A., Sagarra E., Cabrero B., Zaffalon D., Sola R., Pedro-Botet J., Carrión J.A.: Clinical value of thyrotropin receptor antibodies for the differential diagnosis of interferon induced thyroiditis. Exp. Clin. Endocrinol. Diabetes, 2016; 124: 39-44
  Google Scholar
• 4. Bini E.J., Mehandru S.: Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch. Intern. Med., 2004;164: 2371-2376
  Google Scholar
• 5. Costelloe S.J., Wassef N., Schulz J., Vaghijiani T., Morris C., Whiting S., Thomas M., Dusheiko G., Jacobs M., Vanderpump M.P.: Thyroid dysfunction in a UK hepatitis C population treated with interferon-α and ribavirin combination therapy. Clin. Endocrinol., 2010; 73: 249- 256
  Google Scholar
• 6. Doi F., Kakizaki S., Takagi H., Murakami M., Sohara N., Otsuka T., Abe T., Mori M.: Long-term outcome of interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int., 2005; 25: 242-246
  Google Scholar
• 7. Fallahi P., Ferrari S.M., Politti U., Giuggioli D., Ferri C., Antonelli A.: Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int. J. Endocrinol., 2014; 2014: 935131
  Google Scholar
• 8. Fried M. W.: Side effects of therapy of hepatitis C and their management. Hepatology, 2002; 36 (5 Suppl. 1): S237-S244
  Google Scholar
• 9. Friedrich-Rust M., Theobald J., Zeuzem S., Bojunga J.: Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J. Viral Hepat., 2009; 16: 168-177
  Google Scholar
• 10. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat., 1999; 6: 35-47
  Google Scholar
• 11. Hsieh M.C., Yu M.L., Chuang W.L., Shin S.J., Dai C.Y., Chen S.C., Lin Z.Y., Hsieh M.Y., Liu J.F., Wang L.Y., Chang W.Y.: Virologic factors related to interferon-α-induced thyroid dysfunction in patients with chronic hepatitis C. Eur. J. Endocrinol., 2000; 14: 431-437
  Google Scholar
• 12. Huang M.J., Tsai S.L., Huang B.Y., Sheen I.S., Yeh C.T., Liaw Y.F.: Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin. Endocrinol., 1999; 50: 503-509
  Google Scholar
• 13. Hwang Y., Kim W., Kwon S.Y., Yu H.M., Kim J.H., Choe W.H.: Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C. Korean J. Intern. Med., 2015; 30: 792-800
  Google Scholar
• 14. Jamil K.M., Leedman P.J., Kontorinis N., Tarquinio L., Nazareth S., McInerney M., Connelly C., Flexman J., Burke V., Metcalf C., Cheng W.: Interferon-induced thyroid dysfunction in chronic hepatitis C. J. Gastroenterol. Hepatol., 2009; 24: 1017-1023
  Google Scholar
• 15. Kabbaj N., Guedira M.M., El Atmani H., El Alaoui M., Mohammadi M., Benabed K., Lachkar H., Benaissa A.: Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann. Endocrinol., 2006; 67: 343-347
  Google Scholar
• 16. Kakizaki S., Takagi H., Murakami M., Takayama H., Mori M.: HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C. J. Hepatol., 1999; 30: 794-800
  Google Scholar
• 17. Kee K.M., Lee C.M., Wang J.H., Tung H.D., Changchien C.S., Lu S.N., Wang P.W.: Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J. Gastroenterol. Hepatol., 2006; 21: 319-326
  Google Scholar
• 18. Labbadia G., Martocchia A., Mammarella A., Paoletti V., Rocco A., Benvenuto R., Antonella P., Rosaria D., Trabace S., Musca A., Falaschi P.: Association between human leukocyte antigen (HLA) and interferon-induced thyroid diseases in four patients with HCV-related chronic hepatitis. Neuro. Endocrinol. Lett., 2005; 26: 109-112
  Google Scholar
• 19. Maiga I., Valdes-Socin H., Thiry A., Delwaide J., Sidibe AT., Beckers A.: Alpha interferon induced hyperthyroidism: a case report and review of the literature. Rev. Med. Liege, 2015; 70: 390-394
  Google Scholar
• 20. Mandac J.C., Chaudhry S., Sherman K.E., Tomer Y.: The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology, 2006; 43: 661-672
  Google Scholar
• 21. Masood N., Ghori R., Memon A., Memon S., Memon K.I., Memon I., Jaffri M., Baloch G.H.: Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection. J. Coll. Physicians Surg. Pak., 2008; 18: 347-351
  Google Scholar
• 22. Moncoucy X., Leymarie F., Delemer B., Lévy S., Bernard-Chabert B., Bouché O., Jolly D., Diebold M.D., Cadiot G., Thiéfin G.: Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol. Clin. Biol., 2005; 29: 339-345
  Google Scholar
• 23. Nadeem A., Aslam M., Khan D.A., Hussain T., Khan S.A.: Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. J. Coll. Physicians Surg. Pak., 2009; 19: 86-89
  Google Scholar
• 24. Obołończyk L., Siekierska-Hellmann M., Sworczak K.: Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction. Postępy Hig. Med. Dośw., 2007; 62: 309-321
  Google Scholar
• 25. Orságová I., Roznovsky L., Petrousová L., Konecná M., Kabieszová L., Safarcik K., Kloudová A.: Thyroid dysfunction during interferon alpha therapy for chronic hepatitis B and C – twenty years of experience. Klin. Mikrobiol. Infekc. Lek., 2014; 20: 92-97
  Google Scholar
• 26. Tran H.A., Jones T.L., Batey R.G.: The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination interferon-α2bβ and ribavirin. BMC Endocr. Disord., 2005; 5: 8
  Google Scholar
• 27. Vezali E., Elefsiniotis I., Mihas C., Konstantinou E., Saroglou G.: Thyroid dysfunction in patients with chronic hepatitis C: virus – or therapy-related? J. Gastroenterol. Hepatol., 2009; 24: 1024-1029
  Google Scholar
• 28. Zusinaite E., Metskula K., Salupere R.: Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J. Gastroenterol., 2005; 11: 488-491
  Google Scholar

Pełna treść artykułu